The role of targeted therapy and biomarkers in breast cancer treatment

Alison T Stopeck, Ursa Brown-Glaberman, Hong Yuen Wong, Ben Ho Park, Sara E. Barnato, William J. Gradishar, Clifford A. Hudis, Hope S. Rugo

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Breast cancer is the most prevalent life-threatening cancer in women and the second leading cause of cancer associated deaths. Consequently, optimizing breast cancer therapy to increase cure rates in early stage disease and improve life expectancy and palliation for patients with metastasis is a critical need and major area of research in medical oncology. This article focuses on the development of personalized therapy in breast cancer though the use of targeted therapies and their associated biomarkers. Topics reviewed include the historic advances in targeting the HER2 receptor and the current avenues being studied to circumvent resistance; new developments in the management of triple negative and metastatic breast cancer; and the challenges and pitfalls associated with targeting angiogenesis. Using these as examples, many of the innovations and challenges in the treatment of women with breast cancer are explored.

Original languageEnglish (US)
Pages (from-to)807-819
Number of pages13
JournalClinical and Experimental Metastasis
Volume29
Issue number7
DOIs
StatePublished - Oct 2012

Fingerprint

Biomarkers
Breast Neoplasms
Triple Negative Breast Neoplasms
Medical Oncology
Therapeutics
Life Expectancy
Neoplasms
Neoplasm Metastasis
Research

Keywords

  • Angiogenesis
  • Biomarkers
  • Breast cancer
  • Chemotherapy
  • Her2
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Stopeck, A. T., Brown-Glaberman, U., Wong, H. Y., Park, B. H., Barnato, S. E., Gradishar, W. J., ... Rugo, H. S. (2012). The role of targeted therapy and biomarkers in breast cancer treatment. Clinical and Experimental Metastasis, 29(7), 807-819. https://doi.org/10.1007/s10585-012-9496-y

The role of targeted therapy and biomarkers in breast cancer treatment. / Stopeck, Alison T; Brown-Glaberman, Ursa; Wong, Hong Yuen; Park, Ben Ho; Barnato, Sara E.; Gradishar, William J.; Hudis, Clifford A.; Rugo, Hope S.

In: Clinical and Experimental Metastasis, Vol. 29, No. 7, 10.2012, p. 807-819.

Research output: Contribution to journalArticle

Stopeck, AT, Brown-Glaberman, U, Wong, HY, Park, BH, Barnato, SE, Gradishar, WJ, Hudis, CA & Rugo, HS 2012, 'The role of targeted therapy and biomarkers in breast cancer treatment', Clinical and Experimental Metastasis, vol. 29, no. 7, pp. 807-819. https://doi.org/10.1007/s10585-012-9496-y
Stopeck, Alison T ; Brown-Glaberman, Ursa ; Wong, Hong Yuen ; Park, Ben Ho ; Barnato, Sara E. ; Gradishar, William J. ; Hudis, Clifford A. ; Rugo, Hope S. / The role of targeted therapy and biomarkers in breast cancer treatment. In: Clinical and Experimental Metastasis. 2012 ; Vol. 29, No. 7. pp. 807-819.
@article{e72b11a6af7b44708f3a090485cf69e2,
title = "The role of targeted therapy and biomarkers in breast cancer treatment",
abstract = "Breast cancer is the most prevalent life-threatening cancer in women and the second leading cause of cancer associated deaths. Consequently, optimizing breast cancer therapy to increase cure rates in early stage disease and improve life expectancy and palliation for patients with metastasis is a critical need and major area of research in medical oncology. This article focuses on the development of personalized therapy in breast cancer though the use of targeted therapies and their associated biomarkers. Topics reviewed include the historic advances in targeting the HER2 receptor and the current avenues being studied to circumvent resistance; new developments in the management of triple negative and metastatic breast cancer; and the challenges and pitfalls associated with targeting angiogenesis. Using these as examples, many of the innovations and challenges in the treatment of women with breast cancer are explored.",
keywords = "Angiogenesis, Biomarkers, Breast cancer, Chemotherapy, Her2, Targeted therapy",
author = "Stopeck, {Alison T} and Ursa Brown-Glaberman and Wong, {Hong Yuen} and Park, {Ben Ho} and Barnato, {Sara E.} and Gradishar, {William J.} and Hudis, {Clifford A.} and Rugo, {Hope S.}",
year = "2012",
month = "10",
doi = "10.1007/s10585-012-9496-y",
language = "English (US)",
volume = "29",
pages = "807--819",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "7",

}

TY - JOUR

T1 - The role of targeted therapy and biomarkers in breast cancer treatment

AU - Stopeck, Alison T

AU - Brown-Glaberman, Ursa

AU - Wong, Hong Yuen

AU - Park, Ben Ho

AU - Barnato, Sara E.

AU - Gradishar, William J.

AU - Hudis, Clifford A.

AU - Rugo, Hope S.

PY - 2012/10

Y1 - 2012/10

N2 - Breast cancer is the most prevalent life-threatening cancer in women and the second leading cause of cancer associated deaths. Consequently, optimizing breast cancer therapy to increase cure rates in early stage disease and improve life expectancy and palliation for patients with metastasis is a critical need and major area of research in medical oncology. This article focuses on the development of personalized therapy in breast cancer though the use of targeted therapies and their associated biomarkers. Topics reviewed include the historic advances in targeting the HER2 receptor and the current avenues being studied to circumvent resistance; new developments in the management of triple negative and metastatic breast cancer; and the challenges and pitfalls associated with targeting angiogenesis. Using these as examples, many of the innovations and challenges in the treatment of women with breast cancer are explored.

AB - Breast cancer is the most prevalent life-threatening cancer in women and the second leading cause of cancer associated deaths. Consequently, optimizing breast cancer therapy to increase cure rates in early stage disease and improve life expectancy and palliation for patients with metastasis is a critical need and major area of research in medical oncology. This article focuses on the development of personalized therapy in breast cancer though the use of targeted therapies and their associated biomarkers. Topics reviewed include the historic advances in targeting the HER2 receptor and the current avenues being studied to circumvent resistance; new developments in the management of triple negative and metastatic breast cancer; and the challenges and pitfalls associated with targeting angiogenesis. Using these as examples, many of the innovations and challenges in the treatment of women with breast cancer are explored.

KW - Angiogenesis

KW - Biomarkers

KW - Breast cancer

KW - Chemotherapy

KW - Her2

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84868191543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868191543&partnerID=8YFLogxK

U2 - 10.1007/s10585-012-9496-y

DO - 10.1007/s10585-012-9496-y

M3 - Article

C2 - 22692561

AN - SCOPUS:84868191543

VL - 29

SP - 807

EP - 819

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 7

ER -